Studies have found that the mechanistic target of rapamycin (mTOR) inhibitors can block the mTOR signal transduction pathway, produce anti-inflammatory and anti-proliferative effects in cancer, and induce autophagy and apoptosis; thus, these agents are being used in the treatment of NAFLD-associated HCC and other cancers [12]. This evidence concerns the gene MTOR and hepatocellular carcinoma.